Upadacitinib for Prurigo Nodularis

Part of paid clinical trials in East Windsor, New Jersey.

Sponsor
Psoriasis Treatment Center of Central New Jersey
Study ID
NCT06773403
Phase
PHASE4
Status
Terminated

Conditions

  • Prurigo Nodularis

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Not accepted

Interventions

  • Upadacitinib — DRUG
    All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary.

Study Details

A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.

Key Dates

First listed
Jan 14, 2025
Start date
Apr 9, 2024
Status verified
May 2026
Primary completion
Jun 6, 2025
Completion
Jun 6, 2025

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Upadacitinib
    Open-label use of 15mg upadacitinib. Subjects have the option to increase to 30mg at week 8 if the investigator deems it necessary.

Primary Outcome Measure

Reduction in worst-itch numeric rating scale (WI-NRS) at week 12 [ Time Frame: 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Eczema Treatment Center of New JerseyEast WindsorNew Jersey08520-

Find similar trials in East Windsor, NJ

By research site
Eczema Treatment Center of New Jersey· East Windsor, NJ

Related Studies